BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 21079066)

  • 1. "Bullfrog neck," a unique morphologic trait in HIV lipodystrophy: case series and review of the literature.
    Tierney EP; Hanke CW
    Arch Dermatol; 2010 Nov; 146(11):1279-82. PubMed ID: 21079066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).
    Negredo E; Miró O; Rodríguez-Santiago B; Garrabou G; Estany C; Masabeu A; Force L; Barrufet P; Cucurull J; Domingo P; Alonso-Villaverde C; Bonjoch A; Morén C; Pérez-Alvarez N; Clotet B;
    Clin Infect Dis; 2009 Sep; 49(6):892-900. PubMed ID: 19663689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations.
    Gougeon ML; Pénicaud L; Fromenty B; Leclercq P; Viard JP; Capeau J
    Antivir Ther; 2004 Apr; 9(2):161-77. PubMed ID: 15134178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous toxicities of antiretroviral therapy for HIV: part I. Lipodystrophy syndrome, nucleoside reverse transcriptase inhibitors, and protease inhibitors.
    Introcaso CE; Hines JM; Kovarik CL
    J Am Acad Dermatol; 2010 Oct; 63(4):549-61; quiz 561-2. PubMed ID: 20846563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy.
    Pérez-Molina JA; Domingo P; Martínez E; Moreno S
    J Antimicrob Chemother; 2008 Aug; 62(2):234-45. PubMed ID: 18480167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Aurpibul L; Puthanakit T; Lee B; Mangklabruks A; Sirisanthana T; Sirisanthana V
    Antivir Ther; 2007; 12(8):1247-54. PubMed ID: 18240864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efavirenz-associated gynecomastia: report of five cases and review of the literature.
    Jover F; Cuadrado JM; Roig P; Rodríguez M; Andreu L; Merino J
    Breast J; 2004; 10(3):244-6. PubMed ID: 15125753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of nucleoside reverse transcriptase inhibitors in the fat redistribution syndrome.
    Nolan D; Mallal S
    J HIV Ther; 2004 May; 9(2):34-40. PubMed ID: 15238874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review.
    Muñoz-Moreno JA; Fumaz CR; Ferrer MJ; González-García M; Moltó J; Negredo E; Clotet B
    AIDS Rev; 2009; 11(2):103-9. PubMed ID: 19529750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of switching antiretroviral therapy on lipodystrophy and other metabolic complications: a review.
    Hansen BR; Haugaard SB; Iversen J; Nielsen JO; Andersen O
    Scand J Infect Dis; 2004; 36(4):244-53. PubMed ID: 15198179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitochondrial DNA depletion in adipose tissue of HIV-infected patients with peripheral lipoatrophy.
    Buffet M; Schwarzinger M; Amellal B; Gourlain K; Bui P; Prévot M; Deleuze J; Morini JP; Gorin I; Calvez V; Dupin N
    J Clin Virol; 2005 May; 33(1):60-4. PubMed ID: 15797366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prevention and therapy of HIV-associated lipodystrophy syndrome and antiretroviral caused metabolic changes].
    Mauss S
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():49-53. PubMed ID: 16385875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlates of risk of adipose tissue alterations and their modifications over time in HIV-1-infected women treated with antiretroviral therapy.
    Galli M; Ridolfo AL; Adorni F; Cappelletti A; Morelli P; Massetto B; Piazza M; Gianelli E; Vaccarezza M; Gervasoni C; Moroni M
    Antivir Ther; 2003 Aug; 8(4):347-54. PubMed ID: 14518704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antiretroviral treatments-related lipodystrophy syndrome: clinico-pathological findings].
    Lassalle S; Cervera P; Hofman V; Mari M; Dellamonica P; Hofman P
    Ann Pathol; 2005 Sep; 25(4):309-17. PubMed ID: 16327657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential gene expression indicates that 'buffalo hump' is a distinct adipose tissue disturbance in HIV-1-associated lipodystrophy.
    Guallar JP; Gallego-Escuredo JM; Domingo JC; Alegre M; Fontdevila J; Martínez E; Hammond EL; Domingo P; Giralt M; Villarroya F
    AIDS; 2008 Mar; 22(5):575-84. PubMed ID: 18316998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An introduction to nucleoside and nucleotide analogues.
    Squires KE
    Antivir Ther; 2001; 6 Suppl 3():1-14. PubMed ID: 11678469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
    Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
    HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors in human immunodeficiency virus/acquired immunodeficiency syndrome patients undergoing antiretroviral therapy in the state of Pernambuco, Brazil: a case-control study.
    Gelenske T; e Farias FA; de Alencar Ximenes RA; de Melo HR; de Albuquerque Mde F; de Carvalho EH; de Medeiros Barros Z; Diniz GT; Filho Dde B
    Metab Syndr Relat Disord; 2010 Jun; 8(3):271-7. PubMed ID: 20158442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen.
    Fischl MA; Collier AC; Mukherjee AL; Feinberg JE; Demeter LM; Tebas P; Giuliano M; Dehlinger M; Garren K; Brizz B; Bassett R
    AIDS; 2007 Jan; 21(3):325-33. PubMed ID: 17255739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.
    Arranz Caso JA; López JC; Santos I; Estrada V; Castilla V; Sanz J; Sanz J; Molina JP; Fernández Guerrero M; Górgolas M
    HIV Med; 2005 Sep; 6(5):353-9. PubMed ID: 16156884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.